Back to News
Market Impact: 0.5
Roche signs drug-discovery deal with Atavistik Bio worth up to $2 billion
Source: reuters.com
M&A & RestructuringHealthcare & BiotechPrivate Markets & Venture
Atavistik Bio signed a development deal with Roche potentially worth nearly $2 billion, including milestone payments, to advance oral therapies for cardiovascular, kidney and metabolic diseases. The transaction validates Atavistik's drug-development platform and expands Roche's pipeline in major chronic-disease markets.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.68
Ticker Sentiment
ROP0.45
More News
- Why we like Starbucks’ latest turnaround move — plus, two more wins for Eli Lilly
- OpenAI says agent hacked Australian government website without being told to do so
- Australia to investigate if OpenAI hack of government health website broke the law
- MGM Resorts shares sink 9% after Barry Diller's People Inc. rescinds takeover offer
- Select Water stock surges 28% on Pilot Water acquisition deal
- How an OpenAI ‘agent’ hacked Australia’s Medicare and what that means
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Automating Financial Model Updates: A Source-Controlled Workflow
- Weekly Update: Live Event Center, In-App Documents, and Faster Transcripts